A new study in The Journal of Clinical Endocrinology & Metabolism has revealed a concerning paradox in the management of osteoporosis in the United States. While the use of drug therapies for the bone-weakening disease has increased over the last decade, a significant and persistent trend of underdiagnosis means millions of high-risk patients are missing […]
